Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

An isolated recombinant nucleic acid molecule encoding a polypeptide or polypeptide complex according to Formula I:

• wherein:
• A1 comprises a first antigen recognizing molecule that binds to an effector cell antigen, wherein A1 comprises an anti-CD3 binding molecule comprising complementarity determining regions (CDRs):
• HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of A1 comprise:
• HC-CDR1:
• SEQ ID NO:
• 1, HC-CDR2:
• SEQ ID NO:
• 2, and HC-CDR3:
• SEQ ID NO:
• 3;
• and A1 comprises CDRs:
• LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of A1 comprise LC-CDR1:
• SEQ ID NO:
• 4, LC-CDR2:
• SEQ ID NO:5, and LC-CDR3:
• SEQ ID NO:
• 6;
• P1 comprises a peptide that binds to A1, wherein P1 comprises an amino acid sequence according to U1-U2-C-U4-P-U6-U7-U8-U9-U10-U11-U12-C-U14 and U1 is selected from D, Y, F, I, N, V, H, L, A, T, S, and P;
• U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S;
• U4 is selected from G and W;
• U6 is selected from E, D, V, and P;
• U7 is selected from W, L, F, V, G, M, I, and Y;
• U8 is selected from E, D, P, and Q;
• U9 is selected from E, D, Y, V, F, W, P, L, and Q;
• U10 is selected from S, D, Y, T, I, F, V, N, A, P, L, and H;
• U11 is selected from I, Y, F, V, L, T, N, S, D, A, and H;
• U12 is selected from F, D, Y, L, I, V, A, N, T, P, S, G, and H;
• and U14 is selected from D, Y, N, F, I, P, V, A, T, H, L, M, and S;
• L1 comprises a linking moiety that connects A1 to P1 and is a substrate for a tumor specific protease;
• H1 comprises a half-life extending molecule;
• and
• A2 comprises a second antigen recognizing molecule that binds to prostate-specific membrane antigen (PSMA).